Top Companies in the Cell and Gene Therapy for Oncology Market & Their Offerings
| Companies | Headqaurters | Offerings |
| Amgen Inc. | California, U.S. | Develops CAR-T and bispecific T-cell engager therapies (e.g., Blincyto) and advanced immuno-oncology and cell therapy pipelines for blood cancers. |
| Novartis AG | Basel, Switzerland | Pioneer in CAR-T therapy (Kymriah) for leukemia and lymphoma, focusing on personalized cell-based cancer treatments. |
| Gilead Sciences, Inc. | California, U.S. | Through Kite Pharma offers CAR-T therapies (Yescarta, Tecartus) for lymphoma and multiple myeloma. |
| bluebird bio, Inc. | Massachusetts, U.S. | Specializes in gene and cell therapies for hematologic cancers and genetic diseases using lentiviral gene modification. |
| Bristol Myers Squibb Company | New York, U.S. | Provides CAR-T therapies (Breyanzi, Abecma) and invests heavily in next-generation oncology cell therapies. |
| Legend Biotech | Somerset, New Jersey, U.S. | Focuses on CAR-T therapy (Carvykti) for multiple myeloma in collaboration with Johnson & Johnson. |
| JW Therapeutics | Shanghai, China | Develops CAR-T cell therapies for hematologic malignancies, including relapsed/refractory lymphomas. |
What are the Recent Developments in the Cell and Gene Therapy for Oncology Market? 
- In March 2026, Merck & Co. signed an MoU with Cyto-Facto to strengthen its cell and gene therapy manufacturing capabilities in the Asia-Pacific region. The collaboration focuses on improving lentiviral vector production and optimizing advanced manufacturing processes to support next-generation oncology therapies.
- In January 2026, Siren Biotechnology received U.S. FDA clearance for its first Investigational New Drug (IND) application, marking its transition into clinical-stage development. The therapy focuses on AAV-based immuno-gene therapy for treating recurrent high-grade glioma, a highly aggressive brain tumor. This milestone highlights growing innovation in oncology gene therapies along with increasing regulatory support for next-generation cancer treatments.
Supply Chain Analysis
R&D
- Research and development in cell and gene therapies for oncology is progressing quickly, with a strong focus on improving CAR-T cell effectiveness, expanding applications to solid tumors, and advancing in vivo gene editing technologies to achieve better patient outcomes.
- Key Players: Novartis, Gilead Sciences (Kite Pharma), Bristol Myers Squibb, and Fate Therapeutics
Clinical Trials
- Clinical trials in oncology cell and gene therapies are progressing quickly, targeting hard-to-treat cancers such as lung cancer, prostate cancer, and glioblastoma. They focus on innovative approaches like CAR T-cell therapy, oncolytic viruses, and gene-modified stem cells to enhance immune response against tumors.
- Key players: Novartis, Gilead Sciences, Bristol Myers Squibb, AstraZeneca, and Merck & Co.
Patient Support and Services
- Patient support in oncology cell and gene therapies is centered on guiding patients through complex treatment journeys like CAR-T therapy by providing personalized care coordination, financial aid, travel assistance, and end-to-end logistical support. These services are often delivered through specialized patient support programs and treatment hubs to ensure smoother access to advanced therapies.
- Key Players: Novartis, Gilead Sciences (Kite Pharma), Bristol Myers Squibb, and Johnson & Johnson
Market Growth
The global cell and gene therapy for oncology market size was estimated at USD 14.82 billion in 2025 and is predicted to increase from USD 18.48 billion in 2026 to approximately USD 134.53 billion by 2035, expanding at a CAGR of 24.68% from 2026 to 2035.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking